Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

199
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
199
Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs01:21

Fundamental Mathematical Principles in Pharmacokinetics: Calculus and Graphs

683
The fundamental mathematical principles, such as calculus and graphs, play crucial roles in analyzing drug movement and determining pharmacokinetic parameters. Differential calculus examines rates of change and helps to determine the dissolution rate of drugs in biofluids, as well as how drug concentrations change over time. For instance, it can help calculate the rate of elimination of a drug from the body based on its concentration-time profile.
On the other hand, integral calculus focuses on...
683
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

22
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
22
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

70
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
70
Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

18
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
18

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of 340B entity eligibility with changes in hospital financial performance.

Health affairs scholar·2026
Same author

Principles and practices for successful gene therapy innovative contracting: Insights from a multistakeholder convening.

Journal of managed care & specialty pharmacy·2026
Same author

Cost-effectiveness thresholds used in the United States vs most favored nations.

Health affairs scholar·2026
Same author

The inaugural HEMA report: a missed opportunity for comprehensive value assessment.

Journal of comparative effectiveness research·2026
Same author

The timeliness of health plan drug coverage policy changes to FDA label revisions.

Health affairs scholar·2026
Same author

Communication of launch prices by drug companies, 2022-2024.

The American journal of managed care·2026
Same journal

Development and Validation of a Brief Healthcare Insecurity Scale in a Sample of U.S. Adults Living with and without HIV.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

A Competency Framework for Health Technology Assessment Expertise: Results from a Delphi Study.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Physician-led Switching from Reference Biologics to Biosimilars: What is the Effect on selected Health-Related Outcomes and Costs for IBD Patients in Germany?

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020-2023).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Interpreting the Economic Value of TPEx in Recurrent or Metastatic HNSCC: The Importance of Decision Context, Utility Timing, and Treatment Burden.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same journal

Development, use and psychometric properties of vision and hearing bolt-ons for EQ-5D-3L and EQ-5D-5L: a systematic review.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
See all related articles

Related Experiment Video

Updated: May 13, 2025

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

5.9K

Identifying the Influential Dynamic Inputs in Cost-Effectiveness Analyses.

Melanie D Whittington1, Joshua T Cohen1, Peter J Neumann1

  • 1Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|April 14, 2025
PubMed
Summary
This summary is machine-generated.

Dynamic pricing models significantly alter cost-effectiveness estimates compared to static approaches, particularly for long-term treatments. Post-exclusivity drug pricing is crucial for chronic care cost-effectiveness analysis.

Keywords:
cost-effectiveness analysishealth technology assessmentvalue assessment

More Related Videos

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
08:24

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies

Published on: August 25, 2023

577
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Related Experiment Videos

Last Updated: May 13, 2025

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

5.9K
The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
08:24

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies

Published on: August 25, 2023

577
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

14.3K

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Clinical Trial Analysis

Background:

  • Traditional cost-effectiveness analyses (CEAs) often use static pricing, which may not accurately reflect real-world economic dynamics.
  • Changes in drug pricing over time, especially post-loss of exclusivity, can substantially impact the perceived value of treatments.
  • Understanding the influence of dynamic inputs is crucial for accurate healthcare resource allocation.

Purpose of the Study:

  • To compare cost-effectiveness estimates derived from static versus dynamic pricing models.
  • To identify which dynamic input factors most significantly influence cost-effectiveness outcomes.
  • To evaluate these approaches across different treatment scenarios (chronic vs. catastrophic conditions, long-term vs. one-time treatments).

Main Methods:

  • Economic modeling experts convened to identify dynamic cost-effectiveness analysis inputs and modeling approaches.
  • Static and dynamic cost-effectiveness estimates were calculated for four distinct case studies.
  • The study analyzed scenarios including chronic and catastrophic conditions, and treatments administered once or over extended periods.

Main Results:

  • Dynamic cost-effectiveness estimates were consistently more favorable than static estimates across all cases.
  • The difference ranged from 82% (chronic treatment, chronic condition) to 27% (one-time treatment, catastrophic condition).
  • For long-term treatments, post-loss-of-exclusivity pricing was the most influential dynamic factor; for one-time treatments, baseline age and discount rate were more impactful than price changes.

Conclusions:

  • Dynamic modeling approaches yield substantially different, often more favorable, cost-effectiveness estimates compared to static methods, especially for treatments with extended durations.
  • Accurate estimation of price changes, particularly after loss of market exclusivity, is a critical area for future research in pharmacoeconomics.
  • Dynamic modeling enhances the precision of cost-effectiveness assessments for healthcare decision-making.